Ligand Pharmaceuticals | LGND - Ebit

Stock Price
190.01
Daily Change
6.36 3.46%
Monthly
-4.14%
Yearly
60.08%
Q1 Forecast
178.28

Ligand Pharmaceuticals reported $158.89M in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
Agenus USD -13.31M 19.08M Mar/2025
Amgen USD 3.96B 464M Dec/2025
Anika Therapeutics USD -4.28M 3.58M Mar/2025
Arrowhead Research USD 40.81M 17.01M Dec/2025
Baxter International USD -214.2M 415.4M Dec/2025
Bristol-Myers Squibb USD 3.47B 567M Dec/2025
Eli Lilly USD 8.99B 1.57B Dec/2025
Enanta Pharmaceuticals USD -23.54M 6.31M Dec/2024
Enviri Corporation USD 37.37M 5.2M Sep/2024
Gilead Sciences USD 2.96B 551M Dec/2025
GlaxoSmithKline GBP 1.44B 1.35B Dec/2025
Glaxosmithkline GBP 3.76B 1.69B Sep/2025
Heron Therapeutics USD -4.46M 5.76M Sep/2024
Insmed USD -249.71M 11.64M Dec/2025
Intrexon USD -26.3M 2.91M Jun/2024
Ionis Pharmaceuticals USD -160.18M 304.96M Sep/2025
Karyopharm Therapeutics USD -26.28M 1.84M Sep/2024
Ligand Pharmaceuticals USD 158.89M 115.32M Sep/2025
MacroGenics USD 20.16M 55.51M Sep/2025
Merck USD 6.24B 1.32B Dec/2025
Pacira USD 13.15M 2.92M Sep/2025
Pfizer USD 4.65B 71M Dec/2025
Rigel Pharmaceuticals USD 447K 1.52M Jun/2024
Veracyte USD 23.11M 8.8M Sep/2025